Menière's disease affects roughly 0.2% of the population — approximately 615,000 people in the United States alone — with peak onset between ages 40 and 60. For those living with it, the unpredictable vertigo attacks, progressive sensorineural hearing loss, tinnitus, and aural fullness are not just clinical symptoms; they are a profound erosion of quality of life. Mesenchymal stem cell therapy is being investigated as a novel approach to Menière's disease, targeting the underlying biology — endolymphatic hydrops, cochlear inflammation, and spiral ganglion degeneration — rather than merely suppressing symptoms. [1]

What makes Menière's disease difficult to treat. Current standard-of-care — low-sodium diet, diuretics, betahistine, and in severe cases intratympanic gentamicin or vestibular nerve section — manages symptoms but does not address the underlying pathology. Gentamicin ablation controls vertigo at the cost of vestibular function; surgical options are irreversible and carry their own risks. A therapy that could reduce endolymphatic pressure, dampen cochlear inflammation, and support the survival of auditory and vestibular neurons would represent a genuine advance beyond symptom management. [2]

The biological problem is multi-layered. Menière's disease is pathologically defined by endolymphatic hydrops — an abnormal accumulation of endolymph fluid in the inner ear that distends Reissner's membrane and damages the sensory neuroepithelium. But hydrops alone does not explain the full clinical picture. There is a growing consensus that immune dysregulation, viral triggers, and microvascular dysfunction all contribute to a final common pathway of cochlear and vestibular injury. The key structures at risk are cochlear hair cells (responsible for hearing), spiral ganglion neurons (the primary afferent pathway to the brain), and vestibular hair cells (responsible for balance). [3]

MSC therapy addresses the biology at multiple levels. Rather than targeting a single molecule or pathway, mesenchymal stem cells deploy a broad paracrine program — cytokine modulation, growth factor secretion, extracellular vesicle release, and mitochondrial transfer — that simultaneously addresses inflammation, cellular stress, and tissue repair. This multi-target approach is especially relevant to Menière's disease, where no single drug target has been sufficient to arrest disease progression. [4]

What MSC therapy for Menière's disease means in practice

MSC therapy is not a cure for Menière's disease and is not intended to replace standard medical management. It is an investigational approach being studied for its potential to reduce the frequency and severity of vertigo attacks, slow the progression of hearing loss, and support the long-term health of the auditory-vestibular system — goals that current treatments achieve only partially and often at the cost of function.

How MSC therapy may help Menière's disease: mechanisms of action

Mesenchymal stem cells exert therapeutic effects primarily through their secretome — the complex mixture of bioactive molecules they release — rather than through direct cell replacement. In the context of Menière's disease, four mechanisms are particularly relevant. [5]

Anti-inflammatory modulation of the endolymphatic sac. The endolymphatic sac — the primary site of endolymph resorption and immune surveillance in the inner ear — shows perisaccular fibrosis, immune cell infiltration, and altered cytokine profiles in Menière's patients. MSCs secrete interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), and prostaglandin E2 (PGE2), which collectively shift the local immune environment from a pro-inflammatory Th1/Th17 phenotype toward a regulatory Treg-dominant state. This immunomodulation may reduce the inflammatory component of endolymphatic dysfunction and improve fluid homeostasis. [6]

Strial microvascular protection. The stria vascularis — the ion-transporting epithelium that generates the endocochlear potential essential for hearing — is highly metabolically active and exquisitely sensitive to oxidative stress. MSC-derived vascular endothelial growth factor (VEGF), angiopoietin-1, and hepatocyte growth factor (HGF) support microvascular integrity and reduce endothelial apoptosis, potentially preserving the electrochemical gradient that hair cells depend on for mechanotransduction. [7]

Spiral ganglion neuron survival. Spiral ganglion neurons are the primary sensory neurons of the auditory pathway; their loss is irreversible and correlates directly with speech discrimination deficits. MSCs secrete brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) — neurotrophins with well-established survival-promoting effects on spiral ganglion neurons in vitro and in vivo. Even partial preservation of the spiral ganglion population could translate into clinically meaningful hearing preservation over years of disease progression. [8] [9]

Vestibular hair cell protection. The vestibular end-organs — utricle, saccule, and semicircular canals — are damaged in Menière's disease through the same inflammatory and hydrops-driven mechanisms that affect the cochlea. MSC-derived antioxidant enzymes (superoxide dismutase, catalase) and anti-apoptotic factors (Bcl-2, survivin) may reduce oxidative hair cell death in the vestibular neuroepithelium, potentially contributing to reduced vertigo frequency. [10]

The inner ear is challenging terrain for any therapy

The cochlea and vestibular apparatus are encased in the densest bone in the human body — the otic capsule — and are separated from the systemic circulation by the blood-labyrinthine barrier. These anatomical features protect the inner ear from systemic toxins but also limit access for therapeutic agents. This is why delivery route matters enormously for inner ear MSC therapy, and why much of the current research focuses on optimizing it.

Preclinical evidence: what animal models tell us

The preclinical evidence for MSC therapy in inner ear disorders comes primarily from noise-induced hearing loss, aminoglycoside ototoxicity, and autoimmune inner ear disease models — not from a dedicated Menière's model, which does not exist in rodents. However, the shared mechanisms of cochlear inflammation, oxidative stress, and hair cell/neuron loss make these models informative for understanding how MSCs might behave in the Menière's inner ear. [11]

Noise-induced hearing loss models. In guinea pig and mouse models of acoustic trauma, systemic or intratympanic MSC administration within 24–72 hours of noise exposure significantly reduced auditory brainstem response (ABR) threshold shifts at high frequencies — the region most vulnerable to both noise trauma and Menière's disease. Histological analysis showed reduced outer hair cell loss, decreased cochlear macrophage infiltration, and preserved strial morphology. [12]

Aminoglycoside ototoxicity models. Gentamicin and kanamycin — drugs used clinically to ablate vestibular function in severe Menière's — cause oxidative hair cell death through mitochondrial dysfunction and caspase activation. MSC co-treatment or pretreatment in rodent models reduced hair cell loss by 30–50% and preserved vestibular function as measured by vestibular evoked potentials and swim tests. This is a striking proof-of-concept: MSCs can protect against the very mechanism of injury that current Menière's treatments deliberately inflict. [13]

Autoimmune inner ear disease models. In KLH-induced autoimmune labyrinthitis models, MSC infusion reduced cochlear leukocyte infiltration, lowered perilymph levels of TNF-α and IL-1β, and preserved ABR thresholds compared to untreated controls. The reduction in perilymph cytokine levels correlated with histological preservation of the spiral ganglion and stria vascularis. [14]

Clinical evidence: early human data

Human clinical data on MSC therapy specifically for Menière's disease is extremely limited — there are no randomized controlled trials and only a small number of case reports and open-label series. However, the broader clinical experience with MSC therapy in related auditory conditions (sudden sensorineural hearing loss, noise-induced hearing loss, autoimmune inner ear disease) provides some basis for cautious extrapolation. [15]

~5–15 Published case reports/series of MSC therapy for inner ear disorders — all open-label, no controls
0 Completed randomized controlled trials of MSC therapy specifically for Menière's disease
3–6 Months over which improvements have been reported anecdotally — vertigo frequency reduction and hearing stabilization

What the available data suggests. In published case reports of MSC therapy for inner ear conditions, the most consistent finding is not dramatic hearing improvement but disease stabilization — a halting of the progressive decline that characterizes Menière's. Some patients report reduced vertigo frequency (from 2–4 attacks per month to 0–1), modest pure-tone average improvement (5–15 dB), and subjective reduction in tinnitus severity. These outcomes are modest but clinically meaningful for patients who have been losing ground for years with no other options. [16]

The honest caveat. These reports are uncontrolled, subject to publication bias (positive outcomes are more likely to be written up and published), and involve heterogeneous protocols (different MSC sources, doses, and delivery routes). They should be understood as signals worth investigating — not as evidence of efficacy. Any clinic claiming "proven results" for Menière's disease is making claims the published literature does not support.

Delivery routes: getting MSCs to the inner ear

How MSCs reach the inner ear is arguably the most important variable in therapeutic outcome. Unlike most target organs, the cochlea and vestibular apparatus are not accessible via standard intravenous infusion in sufficient concentrations to reliably exert a therapeutic effect — the blood-labyrinthine barrier, while not as impermeable as the blood-brain barrier, significantly limits passive diffusion of cells and large molecules. Several delivery strategies are under investigation. [17]

Intravenous (IV) infusion. The simplest and least invasive route. MSCs administered intravenously home to sites of inflammation through chemokine receptor-ligand interactions (CXCR4/SDF-1 axis), and systemic immunomodulation may benefit the autoimmune component of Menière's. However, the fraction of infused cells that reach the inner ear is very small — likely well below 1% — and the therapeutic effect is primarily systemic rather than local. Most published case reports use IV delivery, which may explain the modest but consistent outcomes reported.

Intratympanic injection. Delivering MSCs through the tympanic membrane into the middle ear allows diffusion across the round window membrane into the cochlear perilymph. This route achieves much higher local concentrations than IV delivery and bypasses the blood-labyrinthine barrier entirely. Animal studies show robust cell engraftment in the scala tympani and vestibuli following intratympanic MSC injection. The limitation: the round window membrane is thicker in humans than in rodents, and diffusion efficiency is highly variable. Intratympanic delivery remains an active area of research rather than a standardized clinical protocol.

Intra-arterial delivery. Superselective catheterization of the labyrinthine artery — a branch of the anterior inferior cerebellar artery — can deliver MSCs directly to the inner ear circulation. This approach achieves the highest local concentrations of any systemic route and has been used in a small number of neurotology cases. However, the procedure is technically demanding, carries a risk of thromboembolic stroke, and is not suitable for routine clinical use. It remains experimental.

"For Menière's disease, the therapeutic window is probably narrow — you need enough anti-inflammatory and neurotrophic activity in the inner ear to shift the disease trajectory, but not so much that you risk sterile inflammation or vascular compromise. Delivery route is at least as important as cell dose." — Perspective from inner ear regenerative medicine research

Treatment journey: what to expect at VELAR

The Menière's disease treatment journey at VELAR Center follows a structured, assessment-driven protocol designed to match the intervention to the individual patient's disease stage, symptom profile, and treatment goals. [18]

1 Comprehensive neurotological assessment. Audiometry (pure-tone, speech discrimination), vestibular testing (VNG/vHIT), and imaging (MRI with gadolinium to visualize endolymphatic hydrops when indicated).
2 Biomarker evaluation. Inflammatory markers (hs-CRP, IL-6, TNF-α), oxidative stress profile, and immune function assessment to characterize the systemic component of disease.
3 Protocol design. MSC dose, delivery route, and session frequency are determined individually — typically 2–4 IV sessions over 4–8 weeks with audiological monitoring at each visit.
4 Follow-up and monitoring. Repeat audiometry at 3, 6, and 12 months post-treatment to track pure-tone thresholds and speech discrimination. Vertigo diary for attack frequency and severity.

Cost of MSC therapy for Menière's disease in Bangkok

MSC therapy for Menière's disease at VELAR Center is priced individually based on the protocol designed for each patient — typically a structured cycle of 2–4 intravenous sessions. Thailand offers substantially lower treatment costs than equivalent programs in North America, Europe, or Australia while maintaining clinical-grade Wharton's jelly-derived MSCs and ISO-certified laboratory standards. Contact VELAR directly for a personalized assessment and cost breakdown.

Who may benefit most

Based on the mechanisms of action and the pattern of outcomes reported in the limited clinical literature, the patient profile most likely to benefit from MSC therapy for Menière's disease includes individuals who:

Not a substitute for standard care

MSC therapy at VELAR is designed to complement — not replace — the standard medical management of Menière's disease. Patients are expected to continue their prescribed low-sodium diet, diuretic therapy, and vestibular rehabilitation as directed by their primary neurotologist. MSC therapy is an adjunctive strategy targeting disease biology that current treatments do not address.

Limitations and honest assessment

MSC therapy for Menière's disease remains investigational. Key limitations to understand before proceeding:

The right question for someone considering MSC therapy for Menière's disease is not "Will this cure my vertigo and restore my hearing?" — the biology does not support a yes. It is "Given the stage of my disease, the frequency of my attacks, and the trajectory of my hearing loss, is there a credible biological rationale for trying to protect the auditory and vestibular cells I still have, and what does the limited evidence actually suggest about the magnitude of benefit I might expect?" That question has an honest answer.

Frequently Asked Questions

How much does stem cell therapy for Menière's disease cost in Thailand?

Treatment costs range depending on the protocol — typically 2–4 IV MSC sessions. Thailand offers pricing substantially below North American and European equivalents while maintaining GMP-grade MSC production and ISO-certified laboratory standards. Contact VELAR directly for a personalized cost estimate after assessment.

Can stem cell therapy cure Menière's disease?

No. MSC therapy is not a cure for Menière's disease. The realistic goal is disease modification — reducing vertigo attack frequency, slowing hearing loss progression, and supporting the long-term health of the auditory-vestibular system — not eliminating the underlying condition.

How are stem cells delivered for inner ear conditions?

At VELAR, systemic intravenous infusion is the primary route. While the blood-labyrinthine barrier limits direct inner ear access, MSCs exert systemic immunomodulatory effects and home to sites of inflammation. Intratympanic delivery (through the eardrum) achieves higher local concentrations but remains investigational.

How many treatments are needed?

Most protocols involve 2–4 sessions over 4–8 weeks, with follow-up audiometry and vestibular assessment at 3, 6, and 12 months. The optimal number and frequency of sessions for Menière's disease specifically has not been established in controlled trials.

Is MSC therapy safe for Menière's disease patients?

The safety profile of MSC therapy is well-characterized across thousands of patients treated for various indications. Serious adverse events are rare. However, inner ear-specific safety data is limited to small case series. Common transient effects include mild fatigue and low-grade fever for 24–48 hours post-infusion.

Can I continue my Menière's medications during MSC therapy?

Yes. MSC therapy is designed as an adjunct to standard medical management, not a replacement. Patients continue their prescribed low-sodium diet, diuretics, betahistine, and vestibular rehabilitation throughout the treatment period.

References

  1. Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière's disease. Journal of Vestibular Research. 2015;25(1):1-7. doi:10.3233/VES-150549 ↩
  2. Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Menière's disease. Otolaryngology–Head and Neck Surgery. 2020;162(2_suppl):S1-S55. doi:10.1177/0194599820909438 ↩
  3. Merchant SN, Adams JC, Nadol JB. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops? Otology & Neurotology. 2005;26(1):74-81. doi:10.1097/00129492-200501000-00013 ↩
  4. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  5. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  6. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacologica Sinica. 2013;34(6):747-754. doi:10.1038/aps.2013.50 ↩
  7. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  8. Géléoc G, Holt JR. Sound strategies for hearing restoration. Science. 2014;344(6184):1241062. doi:10.1126/science.1241062 ↩
  9. Gillespie LN, Richardson RT, Nayagam BA, Wise AK. Treating hearing disorders with cell and gene therapy. Journal of Neural Engineering. 2014;11(6):065001. doi:10.1088/1741-2560/11/6/065001 ↩
  10. Warnecke A, Mellott AJ, Römer A, et al. Advances in translational inner ear stem cell research. Hearing Research. 2017;353:76-86. doi:10.1016/j.heares.2017.05.006 ↩
  11. Mittal R, Nguyen D, Patel AP, et al. Recent advancements in the regeneration of auditory hair cells and hearing restoration. Frontiers in Molecular Neuroscience. 2017;10:236. doi:10.3389/fnmol.2017.00236 ↩
  12. Kamiya K, Fujinami Y, Goto T, et al. Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes. American Journal of Pathology. 2007;171(1):214-226. doi:10.2353/ajpath.2007.061230 ↩
  13. Kasagi H, Kuhara T, Okada H, Sueyoshi N, Kurihara H. Mesenchymal stem cell transplantation to the mouse cochlea as a treatment models for sensorineural hearing loss. Regenerative Medicine. 2013;8(5):527-539. doi:10.2217/rme.13.52 ↩
  14. Yoo TJ, Du X, Kwon SS. Molecular mechanism of autoimmune hearing loss. Acta Oto-Laryngologica. 2002;122(5):502-507. doi:10.1080/00016480260092345 ↩
  15. Baumgartner WD, Baumgartner JE. Regenerative medicine approaches for inner ear disorders: a review of the current state and future directions. Journal of Clinical Medicine. 2022;11(7):1908. doi:10.3390/jcm11071908 ↩
  16. Kanzaki S, Toyoda M, Umezawa A, Ogawa K. Application of mesenchymal stem cell therapy and inner ear regeneration. Audiology and Neurotology. 2020;25(1-2):55-63. doi:10.1159/000503893 ↩
  17. Havenith S, Versnel H, Agterberg MJ, et al. Spiral ganglion cell and inner hair cell protection in the cochlea: a review of current therapeutic strategies. Frontiers in Neurology. 2010;1:152. doi:10.3389/fneur.2010.00152 ↩
  18. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩